M
Mari M. Kitahata
Researcher at University of Washington
Publications - 225
Citations - 16022
Mari M. Kitahata is an academic researcher from University of Washington. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Cohort. The author has an hindex of 59, co-authored 201 publications receiving 14129 citations. Previous affiliations of Mari M. Kitahata include Harborview Medical Center & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Robert S. Hogg,Viviane D. Lima,Jonathan A C Sterne,Sophie Grabar,Manuel Battegay,M. Bonarek,A d'Arminio Monforte,Anna Esteve,Michael Gill,RJ Harris,Amy C. Justice,A. Hayden,F Lampe,Amanda Mocroft,Jan-Christian Wasmuth,Michael J. Mugavero,S Staszewski,A.I. van Sighem,Mari M. Kitahata,Jodie L. Guest,M Egger,Margaret T May +21 more
TL;DR: Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased between 1996 and 2005, although there is considerable variability between subgroups of patients.
Journal ArticleDOI
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Hasina Samji,Angela Cescon,Robert S. Hogg,Robert S. Hogg,Sharada P. Modur,Keri N. Althoff,Kate Buchacz,Ann N. Burchell,Mardge H. Cohen,Kelly A. Gebo,M. John Gill,Amy C. Justice,Gregory D. Kirk,Marina B. Klein,P. Todd Korthuis,Jeffrey N. Martin,Sonia Napravnik,Sean B. Rourke,Timothy R. Sterling,Michael J. Silverberg,Stephen G. Deeks,Lisa P. Jacobson,Ronald J. Bosch,Mari M. Kitahata,James J. Goedert,Richard D. Moore,Stephen J. Gange +26 more
TL;DR: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Antiretroviral therapy cohort collaboration : life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
Robert S. Hogg,Viviane D. Lima,Jonathan A C Sterne,Sophie Grabar,Manuel Battegay,M. Bonarek,A d'Arminio Monforte,Anna Esteve,Michael Gill,RJ Harris,Amy C. Justice,A. Hayden,F Lampe,Amanda Mocroft,Michael J. Mugavero,S Staszewski,Jan-Christian Wasmuth,A.I. van Sighem,Mari M. Kitahata,Jodie L. Guest,M Egger,Margaret T May +21 more
TL;DR: In this article, the authors compared changes in mortality and life expectancy among HIV-positive individuals on combination antiretroviral therapy in 1996-99, 2000-02, and 2003-05, and stratified by sex, baseline CD4 cell count, and history of injecting drug use.
Journal ArticleDOI
Effect of early versus deferred antiretroviral therapy for HIV on survival.
Mari M. Kitahata,Stephen J. Gange,Alison G. Abraham,Barry Merriman,Michael S. Saag,Amy C. Justice,Robert S. Hogg,Steven G. Deeks,Joseph J. Eron,John T. Brooks,Sean B. Rourke,M. John Gill,Ronald J. Bosch,Jeffrey N. Martin,Marina B. Klein,Lisa P. Jacobson,Benigno Rodriguez,Timothy R. Sterling,Gregory D. Kirk,Sonia Napravnik,Anita Rachlis,Liviana Calzavara,Michael A. Horberg,Michael J. Silverberg,Kelly A. Gebo,James J. Goedert,Constance A. Benson,Ann C. Collier,Stephen E. Van Rompaey,Heidi M. Crane,Rosemary G. McKaig,Bryan Lau,Aimee M. Freeman,Richard D. Moore +33 more
TL;DR: The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy.
Journal ArticleDOI
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Michael J. Silverberg,Bryan Lau,Amy C. Justice,Amy C. Justice,Eric A. Engels,M. John Gill,James J. Goedert,Gregory D. Kirk,Gypsyamber D'Souza,Ronald J. Bosch,John T. Brooks,Sonia Napravnik,Nancy A. Hessol,Lisa P. Jacobson,Mari M. Kitahata,Marina B. Klein,Richard D. Moore,Benigno Rodriguez,Sean B. Rourke,Michael S. Saag,Timothy R. Sterling,Kelly A. Gebo,Natasha Press,Jeffrey N. Martin,Robert Dubrow +24 more
TL;DR: Anal cancer rates were substantially higher for HIV-infected MSM, other men, and women compared with HIV-uninfected individuals, suggesting a need for universal prevention efforts.